Daniel O'Day (Georgios Kefalas for AP)

March 28, 2022 10:52 AM EDTUpdated April 1, 03:28 AM

As Gilead’s stock price gets blitzed after a series of pratfalls, why is Dan O’Day getting a small raise?

Over the past year, Gilead has been subjected to one nasty setback after the next. But it hasn’t even dented Daniel O’Day’s pay package. …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Corvus' early-phase atopic dermatitis data prompt stock rally

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

GSK awaits Nucala decision after FDA target date passes

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges